Thursday, 29 September 2022 14.00 - 15.30 h
Recently the U.S. Food and Drug Administration (FDA) issued a warning letter dated January 7, 2022, due to inadequate investigations into out-of-specification (OOS) test results.
In May and June 2021, the FDA inspected the drug manufacturing facility Professional Disposables International, Inc, located in Orangeburg, New York. During that inspection, the FDA investigators observed specific GMP violations.
According to the Code of Federal Regulations, Sec. 211.192 (Production record review), the following applies:
"All drug product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed. Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed. The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. A written record of the investigation shall be made and shall include the conclusions and followup."
The FDA considers the firm's OOS investigations as inadequate for the following reasons:
In the warning letter, different examples are mentioned. According to the FDA, in all of these examples, the quality unit (QU) "concluded, without adequate scientific justification, that analytical error was the most probable root cause for the original OOS results." The company also failed to initiate a "production review or CAPA at the conclusion of the investigations, including a comprehensive evaluation of the product development, manufacturing validation, previous failing results obtained, and analytical test method."
In response to the warning letter, the FDA now expects the following:
Please see the FDA Warning Letter to Professional Disposables International, Inc. for more information.